GlassScriptPhysician profile
Michael I Wiener
NPI 1922091370
$5,132.69
in general payments reported to CMS, 2019-2025
26 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $1,342 · 2021: $687 · 2022: $517 · 2023: $679 · 2024: $216 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $878.31 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $831.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $490.20 | 2019-2022 | |
| Glaxosmithkline, LLC. | $472.92 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $455.42 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $359.00 | 2019-2025 | |
| Amarin Pharma, INC. | $258.41 | 2019-2022 | |
| Gilead Sciences, INC. | $242.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $218.25 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Myriad Women'S Health, INC. | $182.85 | 2023 | Myrisk |
| Madrigal Pharmaceuticals | $148.42 | 2025 | Rezdiffra |
| Arthrosurface Incorporated | $99.86 | 2019 | |
| Arbor Pharmaceuticals, INC. | $98.51 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.47 | 2019-2022 | |
| Genentech USA, INC. | $68.91 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $51.91 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $47.35 | 2022 | |
| Medtronic Minimed, INC. | $18.88 | 2019 | |
| Phadia US INC. | $16.18 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.82 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $14.95 | 2020 | |
| Eisai INC. | $14.80 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.11 | 2023 | Horizant |
| Dynavax Technologies Corporation | $12.25 | 2019 | |
| Sanofi Pasteur INC. | $12.24 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wiener listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.